MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Stan Smith Buys 75,000 Shares

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Stan Smith acquired 75,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was purchased at an average cost of $1.34 per share, for a total transaction of $100,500.00. Following the completion of the purchase, the director directly owned 1,519,178 shares of the company’s stock, valued at $2,035,698.52. The trade was a 5.19% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

MAIA Biotechnology Price Performance

Shares of NYSEAMERICAN:MAIA opened at $1.35 on Wednesday. The company’s 50 day simple moving average is $1.32 and its 200 day simple moving average is $1.52. The stock has a market capitalization of $82.08 million, a price-to-earnings ratio of -2.01 and a beta of 0.23. MAIA Biotechnology, Inc. has a 1 year low of $0.87 and a 1 year high of $3.19.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its earnings results on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. As a group, analysts anticipate that MAIA Biotechnology, Inc. will post -0.52 EPS for the current fiscal year.

Hedge Funds Weigh In On MAIA Biotechnology

Several hedge funds and other institutional investors have recently bought and sold shares of MAIA. Centric Wealth Management increased its stake in MAIA Biotechnology by 2.0% in the fourth quarter. Centric Wealth Management now owns 586,398 shares of the company’s stock valued at $897,000 after purchasing an additional 11,500 shares in the last quarter. Geode Capital Management LLC increased its stake in MAIA Biotechnology by 9.5% in the fourth quarter. Geode Capital Management LLC now owns 296,740 shares of the company’s stock valued at $454,000 after purchasing an additional 25,684 shares in the last quarter. Corsair Capital Management L.P. bought a new stake in MAIA Biotechnology in the first quarter valued at $140,000. Jane Street Group LLC bought a new stake in MAIA Biotechnology in the fourth quarter valued at $120,000. Finally, Ritholtz Wealth Management bought a new stake in MAIA Biotechnology in the fourth quarter valued at $35,000. Institutional investors and hedge funds own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical?stage biopharmaceutical company developing a proprietary platform for site?specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody?based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high?contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody?radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.